20 completed. 20 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 20 |
| Phase 2 | 4 | Completed 4 |
Follow Standard therapy: new trials by email Literature Review of Standard therapy trials Research Report on Standard therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19 MIR 19 ®, Standard therapy - COVID-19 | Phase 2 / Phase 3 | Completed | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | 984 | 2022-02-10 | 2023-12-27 |
| Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant Best Practice and Internet site with links to existing resources, Internet, Mobile app and Telehealth Intervention, Survey Administration - Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | Completed | Fred Hutchinson Cancer Center | 546 | 2020-10-29 | 2025-01-29 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study Plasma, Standard Therapy - Coronavirus, Coronavirus Infection | Phase 2 / Phase 3 | Completed | Universidad del Rosario | 92 | 2020-08-08 | 2020-11-27 |
| Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 HCQ, Standard therapy - CoVID-19 | Phase 3 | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh | 325 | 2020-03-01 | 2020-08-04 |
| Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) Placebo plus standard therapy, RC18 160 mg plus standard therapy - Systemic Lupus Erythematosus | Phase 3 | Completed | RemeGen Co., Ltd. | 335 | 2019-10-16 | 2023-05-11 |
| Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer Internet-Based Intervention, Best Practice, Quality-of-Life Assessment - Stage II Prostate Cancer, Stage IIA Prostate Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 158 | 2017-10-02 | 2025-01-27 |
| "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department" Ketamine, Normal saline, Metoclopramide - Headache, Intranasal Ketamine | Phase 3 | Completed | Brooke Army Medical Center | 80 | 2016-05-01 | 2018-01-18 |
| Acupuncture for Pain Control After Elective Caesarean Section Standard therapy, Verum acupuncture, Placebo acupuncture - Postoperative Pain | Phase 2 / Phase 3 | Completed | University Medicine Greifswald | 180 | 2015-01-13 | 2021-01-11 |
| A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy - Acute Coronary Syndrome | Phase 3 | Completed | GlaxoSmithKline | 3503 | 2014-06-03 | 2017-06-02 |
| Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases Naderin, Standard Therapy - Malignant Neoplasms, Tuberculosis (TB) | Phase 2 / Phase 3 | Completed | MIPO Clinic | 75 | 2013-05-15 | 2026-06-30 |
| Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations NaCl 3%, Standard therapy - Moderate to Severe Bronchiolitis | Phase 3 | Completed | Raphaelle Jaquet-Pilloud | 120 | 2013-03-01 | 2016-08-19 |
| Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis Placebo plus standard therapy, Belimumab 10 mg/kg plus standard therapy, Standard therapy - Lupus Nephritis | Phase 3 | Completed | Human Genome Sciences Inc., a GSK Company | 448 | 2012-07-12 | 2021-03-19 |
| Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients standard therapy, Everolimus - Lung Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 130 | 2012-02-01 | 2019-03-14 |
| A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Placebo, Belimumab 200 mg SC, Standard therapy - Systemic Lupus Erythematosus | Phase 3 | Completed | Human Genome Sciences Inc., a GSK Company | 839 | 2011-11-16 | 2018-06-06 |
| Effects of Cardiac Rehabilitation on Postoperatory of Coronary Artery Bypass Graft. Combination of four techniques of physiotherapy, Combination of three techniques of physiotherapy, Combination of two techniques of physiotherapy - Complication of CABG | Phase 3 | Completed | Hospital de Clinicas de Porto Alegre | 40 | 2011-01-01 | 2016-03-22 |
| Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock standard therapy, hemoperfusion - Peritonitis, Septic Shock | Phase 3 | Completed | Meditor SAS | 243 | 2010-10-01 | 2013-12-18 |
| The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial Darapladib 160 mg, Placebo, Standard Therapy - Acute Coronary Syndrome | Phase 3 | Completed | GlaxoSmithKline | 13026 | 2009-12-01 | 2017-08-10 |
| Advanced eHealth for Chronic Obstructive Pulmonary Disease (COPD) in Colorado Integrated Care, Standard Therapy - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | University of Colorado, Denver | 511 | 2006-09-01 | 2012-10-05 |
| Statins in Proteinuric Nephropathies Fluvastatin, standard therapy - Chronic Nephropathy, Proteinuria | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 217 | 2003-03-01 | 2010-04-28 |
| Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer dalteparin, standard therapy - Breast Cancer, Colorectal Cancer | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 141 | 1998-12-01 | 2016-07-13 |
COVID-19 (3) · Lupus Erythematosus, Systemic (3) · Acute Coronary Syndrome (2) · Autoimmune Diseases (2) · Cardiovascular Diseases (2) · Prostatic Neoplasms (2) · Atherosclerosis (1) · Breast Neoplasms (1) · Bronchiolitis (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Coronary Disease (1) · Coronavirus Infections (1) · Glomerulonephritis (1)
Alliance for Clinical Trials in Oncology (2) · GlaxoSmithKline (2) · Human Genome Sciences Inc., a GSK Company (2) · Brooke Army Medical Center (1) · Fred Hutchinson Cancer Center (1) · Hospital de Clinicas de Porto Alegre (1) · MIPO Clinic (1) · Mario Negri Institute for Pharmacological Research (1) · Meditor SAS (1) · National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia (1) · Novartis Pharmaceuticals (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Raphaelle Jaquet-Pilloud (1) · RemeGen Co., Ltd. (1) · Universidad del Rosario (1)
United States (9) · Germany (6) · France (5) · Russia (5) · Argentina (4) · Belgium (4) · Brazil (4) · Canada (4) · Colombia (4) · Czechia (4) · Hungary (4) · Italy (4) · Philippines (4) · Spain (4) · Taiwan (4)
Deba P Dhibar, MD (1) · Didier Payen, MD (1) · Fengchun Zhang, M.D. (1) · Jean-Yves Pauchard (1) · Juan M Anaya Cabrera, MD, PhD (1) · K. Scott Baker (1) · Piero Ruggenenti, MD (1) · Scott Okuno, MD (1) · Taras I Usichenko, MD, PhD (1) · William Vandivier, MD (1)
PMID 20671225, PMID 21982651, PMID 25173516, PMID 25862039, PMID 25965709, PMID 27043082, PMID 28077384, PMID 28118533, PMID 29018021, PMID 29671280, PMID 29807477, PMID 30081846, PMID 30371283, PMID 30615259, PMID 31488402, PMID 32871021, PMID 32937045, PMID 33558436, PMID 33568389, PMID 33687069, PMID 34508693, PMID 34531304, PMID 34560137, PMID 34890060, PMID 35226080, PMID 35283454, PMID 35761219, PMID 36058429, PMID 36302567, PMID 37017254, PMID 37228028, PMID 37463054, PMID 38018702, PMID 38216728, PMID 38724182, PMID 39115551, PMID 39208825, PMID 40244828, PMID 41092329, PMID 42173278
R01CA215134 (1)